00:00Thank you for joining us.
00:02PT Indofarma, TBK, and Kodasaminav reported a loss of more than Rp721 billion throughout 2023.
00:10The management stressed that what is happening now is the accumulation of financial problems that have just been felt in 2023.
00:21Quoted from the annual report, PT Indofarma, TBK reported a loss of Rp721 billion in 2023.
00:29This loss has soared from the previous year at Rp457.62 billion.
00:35The loss of the year was accompanied by clean sales, which fell by 46.59% annually from the position of Rp980.37 billion to Rp523.59 billion in 2023.
00:49From the operational side, the volume of production of Indofarma drugs reached 457.99 million units or increased by 0.5% annually from 2022 to 455.7 million units.
01:04There was also the production of medical equipment from 90,350 units to only 57 units last year.
01:13Indofarma in 2023 recorded a total asset of Rp759.82 billion or fell by 48.71% year-on-year.
01:23Meanwhile, the amount of equity reached minus Rp804.15 billion and the total liability reached Rp1.56 trillion or increased by 5.12% annually.
01:35The Director-General of PT Indofarma, TBK, Yelian Riyani, explained that the decline in INAF's performance in 2023 was mainly caused by the limited working capital.
01:46The management emphasized that what happened at this time was an accumulation of financial problems that were only felt in 2023,
01:53such as unpaid debt problems, which in fact had a negative impact on the negative cash flow.
02:04For more UN videos visit www.un.org
Comments